Advanced Biologics Publishes Benefits of OsteoAMP Growth Factor

Advanced Biologics LLC has published two abstracts in The Bone and Joint Journal that substantiate the differentiation and clinical benefit of OsteoAMP allograft-derived growth factor.

The first abstract, “Osteoinductivity and osteogenicity of leading allograft bone products”, examined the BMP-2 (bone morphogenetic protein-2) content and bone forming potential of OsteoAMP and Osteocel Plus from Nuvasive Inc. In that athymic rat study, products were implanted and assessed for bone formation and measurement of the cellular, mineral, and collagen phase content of BMP-2. Osteocel Plus exhibited increased osteonecrosis over all time periods and no BMP-2 from cells on ELISA analysis. OsteoAMP, on the other hand, displayed approximately 1,000 times the BMP-2 amounts of Osteocel Plus and new bone formation and cellularity increase through all time points.

“Our goal of this paper was to validate the anecdotal evidence we hear on a daily basis from the field,” said Scott Cadotte, vice president of sales and marketing at Advanced Biologics. “This showcases the superiority of OsteoAMP over a leading allogeneic stem cell product.”

In the second abstract, “A blinded multi-centre, clinical and radiological study to evaluate the efficacy of OsteoAMP versus rhBMP-2in TLIF/LLIF procedures”, a total of 254 consecutive patients (383 total levels) were treated with a transforaminal lumbar interbody fusion or lateral lumbar interbody fusion procedure and assessed radiologically. As has previously been shown, OsteoAMP produced faster fusion rates than rhBMP-2 and with much less radiologically evident adverse events such as osteolysis and ectopic bone formation.

OsteoAMP is an allograft-derived growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 and allograft-derived stem cells, such as Osteocel Plus or Trinity Elite. OsteoAMP’s three distinctive formats (granules, compressible sponges and putty) allow surgeons to tailor deliver the technology according to their needs in surgery, according to the company.

Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by the Carlsbad,Calif.-based firm.